Drug Trial Radar · NCT04971447
Extracellular Vesicles and Endothelial Function in Transgender Subjects
Last checked: Nov 20, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
136
Planned (sponsor's estimate)
Start
Aug 2022
Primary completion
Sep 2023
Study completion Jan 2024
Sponsor
- Lead sponsor
- Central Hospital, Nancy, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.
Conditions
- Transgenderism
Interventions
gender affirming hormonal treatment in transgender menDrug
testosterone enanthate
gender affirming hormonal treatment in transgender womenDrug
GnRH agonists + estrogen
Primary outcomes
What the sponsor says the trial is designed to measure.
- pulse wave velocityTime frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.